September 28, 2021
2 min watch
Save
VIDEO: NADIM study update may reposition neoadjuvant therapy for advanced NSCLC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Jae Y. Kim, MD, highlights updated data from the NADIM trial presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
According to Kim, chief of thoracic surgery and associate professor at City of Hope, the 3-year overall survival in both the intent-to-treat and per-protocol populations were “really amazing for patients with stage III disease.”
Reference:
- Provencio M, et al. Abstract OA20.01. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (virtual meeting); Sept. 8-14, 2021.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Kim reports receiving a research grant to his institution from Eli Lily and serving as a consultant for AstraZeneca.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.